Applying evidence-based device care in cardiovascular patients: Which patient with heart failure and what device?

Journal of the Royal College of Physicians of Edinburgh

Volumn 40, Issue 3, 2010, Pages 229-239

  Cleland, J G ^d   Buga, L ^a   Ghosh, J ^b   Nasir, M ^c  

^a Research Fellow in Cardiology   (United Kingdom)

^b Specialist Registrar in Cardiology   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

^d NONE

Author keywords

Cardiac resynchronisation therapy; Heart failure; Implantable cardiac defibrillators; Morbidity; Mortality; Symptoms

Indexed keywords

ANTIARRHYTHMIC AGENT;

ARTICLE; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; DEFIBRILLATION; DEFIBRILLATOR; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HUMAN; MORTALITY; PATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROGNOSIS; SECONDARY PREVENTION; SUDDEN DEATH; SYSTOLIC DYSFUNCTION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

CARDIAC RESYNCHRONIZATION THERAPY DEVICES; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC;

EID: 77957334128     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2010.311     Document Type: Article

References (94)

1. Torabi A, Rigby AS, Cleland JG. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol 2009; 55: 79-81. doi: 10.1016/j. jacc.2009.05.080
2. Torabi A, Cleland JG, Khan NK et al. The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J 2008; 29: 859-70. doi: 10.1093/eurheartj/ehn096
3. Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999; 1: 41-5. doi: 10.1016/S1388-9842(99)00009-4
4. Remme WJ, Cleland JG, Erhardt L et al. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. Eur J Heart Fail 2007; 9: 1128-35. doi: 10.1016/j.ejheart.2007.07.014
5. Cleland JG, Freemantle N, Ball SG et al. The heart failure revascularisation trial (HEART): rationale, design and methodology. Eur J Heart Fail 2003; 5: 295-303. doi: 10.1016/S1388-9842(03)00056-4
6. Coletta AP, Cleland JG, Cullington D et al. Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. Eur J Heart Fail 2008; 10: 917-20. doi: 10.1016/j.ejheart.2008.07.006
7. Cleland JGF, Orn S, Romo M et al. Incidence, severity and timing of neurological events after a major myocardial infarction. Eur J Heart Fail 2003; 2(Suppl 2): 81-2. doi: 10.1016/S1567-4215(03)90253-0
8. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41. doi: 10.1016/S0140-6736(01)06178-5 Erratum in: Lancet 2001; 358: 1556.
9. Amarenco P, Bogousslavsky J, Callahan A et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59. doi: 10.1056/NEJMoa061894
10. Cleland JG. Is aspirin 'the weakest link' in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 2002; 44: 275-92. doi: 10.1053/pcad.2002.31597
11. Cleland JG, McMurray JJ, Kjekshus J et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009; 54: 1850-9. doi: 10.1016/j.jacc.2009.06.041
12. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13. doi: 10.1016/S0140-6736(03)13800-7
13. Cleland JG, Rigby AS, McDonagh T et al. The National Audit of Heart Failure for England and Wales 2008-09. In submission.
14. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-9. doi: 10.1056/NEJMoa051530
15. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9. doi: 10.1056/NEJMoa052256
16. Cleland JG, Tendera M, Taylor J. Prognosis in heart failure with a normal ejection fraction. N Engl J Med 2007; 357: 829-30. doi: 10.1056/NEJMc076179
17. Cleland JG, Nasir M, Tageldien A. Cardiac resynchronization therapy or atriobiventricular pacing - what should it be called? Nat Clin Pract Cardiovasc Med 2007; 4: 90-101. doi: 10.1038/ncpcardio0794
18. Moss AJ, Hall WJ, Cannom DS et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-38. doi: 10.1056/NEJMoa0906431
19. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37. doi: 10.1056/NEJMoa043399
20. Cleland JG, Coletta AP, Freemantle N et al. Clinical trials update from the American Heart Association Meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II and PACE. Eur J Heart Fail 2010; 12: 197-201. doi: 10.1093/eurjhf/hfp199
21. Rose EA, Gellins AC, Moskowitz AJ et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 1435-43. doi: 10.1056/NEJMoa012175
22. Slaughter MS, Rogers JG, Milano CA et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-51. doi: 10.1056/NEJMoa0909938
23. Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-53. doi: 10.1056/NEJMoa013168
24. Cleland JGF, Daubert J-C, Erdmann E et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization - Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27: 1928-32. doi: 10.1093/eurheartj/ehl099
25. Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New Engl J Med 2004; 350: 2140-50. doi: 10.1056/NEJMoa032423
26. Daubert J-C, Gold MR, Abraham WT et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. J Am Coll Cardiol 2009;54: 1837-46. doi: 10.1016/j.jacc.2009.08.011
27. National Institute for Health and Clinical Excellence. TA120 Heart failure - cardiac resynchronisation: guidance. London: NICE; 2007. Available from: http: //guidance.nice.org.uk/TA120/Guidance/pdf/English
28. Scottish Intercollegiate Guidelines Network. Management of chronic heart failure. Edinburgh: SIGN; 2007. Available from: http: //www.sign.ac.uk/pdf/sign95.pdf
29. European Society of Cardiology, Heart Failure Association of the ESC (HFA), European Society of Intensive Care Medicine (ESICM) et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.
30. Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
31. National Institute for Health and Clinical Excellence. Arrhythmia - implantable cardioverter defibrillators (ICDs). London: NICE; 2006. Available from: http: //guidance.nice.org.uk/TA095
32. Scottish Intercollegiate Guidelines Network. Cardiac arrhythmias in coronary heart disease. Edinburgh: SIGN; 2007. Available from: http: //www.sign.ac.uk/pdf/sign94.pdf
33. Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death - executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006; 27: 2099-140.
34. The antiarrhythmics versus implantable defibrillators (AVID) investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-83. doi: 10.1056/NEJM199711273372202
35. Connolly SJ, Gent M, Roberts RS et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-302.
36. Kuck K-H, Cappato R, Siebels J et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-54.
37. Connolly SJ, Hallstrom AP, Cappato R et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000; 21: 2071-8. doi: 10.1053/euhj.2000.2476
38. Kadish A, Dyer A, Daubert JP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-8. doi: 10.1056/NEJMoa033088
39. Strickberger SA, Hummel JD, Bartlett TG et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707-12. doi: 10.1016/S0735-1097(03)00297-3
40. Bänsch D, Antz M, Boczor S et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105: 1453-8. doi: 10.1161/01.CIR.0000012350.99718.AD
41. Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch trial investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997; 337: 1569-75. doi: 10.1056/NEJM199711273372201
42. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-40. doi: 10.1056/NEJM199612263352601
43. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83. doi: 10.1056/NEJMoa013474
44. Buxton AE, Lee KL, DiCarlo L et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 2000; 342: 1937-45. doi: 10.1056/NEJM200006293422602
45. Healey JS, Hallstrom AP, Kuck KH et al. Role of the implantable defibrillator among elderly patients with a history of lifethreatening ventricular arrhythmias. Eur Heart J 2007; 28: 1746-9. doi: 10.1093/eurheartj/ehl438
46. Cleland JG, Freemantle N, Kaye G et al. Clinical trials update from the American Heart Association meeting: omega-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE. Eur J Heart Failure 2004; 6: 109-15. doi: 10.1016/j.ejheart.2003.12.002
47. Cleland JG, Buga L. Device therapy: defibrillators - a shocking therapy for cardiomyopathy? Nat Rev Cardiol 2010; 7: 69-70. doi: 10.1038/nrcardio.2009.233
48. Hohnloser SH, Kuck KH, Dorian P et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-8. doi: 10.1056/NEJMoa041489
49. Steinbeck G, Andresen D, Seidl K et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361: 1427-36. doi: 10.1056/NEJMoa0901889
50. Raviele A, Bongiorni MG, Brignole M. Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The BEta-blocker STrategy plus ICD trial. Europace 2005; 7: 327-37. doi: 10.1016/j. eupc.2005.03.003
51. Wilkoff BL, Cook JR, Epstein AE et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. JAMA 2002; 288: 3115-23. doi: 10.1001/jama.288.24.3115
52. Cleland JG, Coletta AP, Clark AL et al. Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. Eur J Heart Fail 2009; 11: 622-30. doi: 10.1093/eurjhf/hfp071
53. Huang DT, Sesselberg HW, McNitt S et al. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol 2007; 18: 833-8. doi: 10.1111/j.1540-8167.2007.00857.x
54. Lee DS, Krahn AD, Healey JS et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010; 55: 774-82. doi: 10.1016/j.jacc.2009.11.029
55. Bardy GH, Smith WM, Hood MA. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363: 36-44. doi: 10.1056/NEJMoa0909545
56. Cleland JG, Coletta AP, Yassin A et al. Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, metaanalysis of Cox-2 studies, HAT, ON-TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON-HF and REVERSE. Eur J Heart Fail 2008; 10: 614-20. doi: 10.1016/j.ejheart.2008.05.003
57. Luu M, Stevenson WG, Stevenson LW et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989; 80: 1675-80.
58. Faggiano P, d'Aloia A, Gualeni A et al. Mechanisms and immediate outcome of in-hospital cardiac arrest in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2001; 87: 655-7. doi: 10.1016/S0002-9149(00)01450-8
59. Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-80. doi: 10.1056/NEJM200103223441202
60. Leclercq C, Walker S, Linde C et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23: 1780-7. doi: 10.1053/euhj.2002.3232
61. Higgins SL, Hummel JD, Niazi IK et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42: 1454-9. doi: 10.1016/S0735-1097(03)01042-8
62. Young J, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA 2003; 289: 2685-94. doi: 10.1001/jama.289.20.2685
63. Abraham WT, Young JB, León AR et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004; 110: 2864-8. doi: 10.1161/01. CIR.0000146336.92331.D1
64. Cleland JG, Daubert J-C, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49. doi: 10.1056/NEJMoa050496
65. Beshai JF, Grimm RA, Nagueh SF et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007; 357: 2461-71. doi: 10.1056/NEJMoa0706695
66. Linde C, Abraham WT, Gold MR et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008; 52: 1834-43. doi: 10.1016/j.jacc.2008.08.027
67. Gras D, Lunati M, Wellens HJ et al. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace 2007; 9: 516-22. doi: 10.1093/europace/eum080
68. Cleland JG, Calvert M, Verboven Y et al. Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac REsynchronization-Heart Failure (CARE-HF) study. Am Heart J 2009; 157: 457-66. doi: 10.1016/j.ahj.2008.11.006
69. Ghio S, Freemantle N, Scelsi L et al. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Failure 2009; 11: 480-8. doi: 10.1093/eurjhf/hfp034
70. Cleland JG, Freemantle N, Daubert J-C et al. Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF Study. Heart 2008; 94: 278-83. doi: 10.1136/hrt.2007.128991
71. Berger R, Shankar A, Fruhwald F et al. Relationships between cardiac resynchronization therapy and NT-BNP in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the CARE-HF trial. Eur Heart J 2009; 30: 2109-16. doi: 10.1093/eurheartj/ehp210
72. Cleland JG, Tavazzi L, Daubert J-C et al. Cardiac resynchronization therapy. Are modern myths preventing appropriate use? J Am Coll Cardiol 2009; 53: 608-11. doi: 10.1016/j.jacc.2008.10.040
73. Whinnett ZI, Davies JE, Willson K et al. Haemodynamic effects of changes in atrioventricular and interventricular delay in cardiac resynchronisation therapy show a consistent pattern: analysis of shape, magnitude and relative importance of atrioventricular and interventricular delay. Heart 2006; 92: 1628-32. doi: 10.1136/hrt.2005.080721
74. Raphael CE, Whinnett ZI, Davies JE et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart 2009; 95: 56-62. doi: 10.1136/hrt.2007.134973
75. Cleland J, Freemantle N, Ghio S et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response: a report from the CARE-HF (CArdiac REsynchronisation in Heart Failure) trial. J Am Coll Cardiol 2008; 52: 438-45. doi: 10.1016/j.jacc.2008.04.036
76. Richardson M, Freemantle N, Calvert MJ et al. Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a predefined analysis from the CARE-HF trial. Eur Heart J 2007; 28: 1827-34. doi: 10.1093/eurheartj/ehm192
77. Gervais R, Leclerq C, Shankar A et al. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. Eur J Heart Fail 2009; 11: 699-705. doi: 10.1093/eurjhf/hfp074
78. Wikstrom G, Lundqvist CB, Andren B et al. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J 2009; 30: 782-8. doi: 10.1093/eurheartj/ehn577
79. Cleland JG, Pennell DJ, Ray SG. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003; 362: 14-21. doi: 10.1016/S0140-6736(03)13801-9
80. Uretsky BF, Thygesen K, Daubert JC et al. Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trial. J Card Fail 2008; 14: 670-5. doi: 10.1016/j. cardfail.2008.06.001
81. Leclercq JF, Maisonblanche P, Cauchemez B et al. Respective role of sympathetic tone and of cardiac pauses in the genesis of 62 cases of ventricular fibrillation recorded during Holter monitoring. Eur Heart J 1988; 9: 1276-83.
82. Drew BJ, Ackerman MJ, Funk M. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010; 55: 934-47. doi: 10.1016/j.jacc.2010.01.001
83. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999; 354: 1625-33. doi: 10.1016/S0140-6736(99)02107-8
84. Moss AJ, Liu JE, Gottlieb S et al. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation 1991; 84: 1524-9.
85. Abraham WT, Smith AL, the MIRACLE Study Group. A multivariate assessment of cardiac resynchronization therapy on morbidity and mortality. Eur J Heart Failure 2003; 2(Suppl 1): 148 (Abstract 709).
86. Hummel JP, Lindner JR, Belcik JT et al. Extent of myocardial viability predicts response to biventricular pacing in ischemic cardiomyopathy. Heart Rhythm 2005; 2: 1211-7. doi: 10.1016/j. hrthm.2005.07.027
87. Feldman AM, de Lissovoy LG, Bristow MR et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46: 2311-21. doi: 10.1016/j.jacc.2005.08.033
88. Yao G, Freemantle N, Calvert M et al. The long-term costeffectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007; 28: 42-51. doi: 10.1093/eurheartj/ehl382
89. Clark AL, Goode K, Cleland JG. The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. Eur J Heart Fail 2008; 10: 696-702. doi: 10.1016/j. ejheart.2008.05.001
90. Aranda JM, Carlson ER, Pauly DF et al. QRS duration variability in patients with heart failure. Am J Cardiol 2002; 90: 335-7. doi: 10.1016/S0002-9149(02)02479-7
91. Bourge RC, Abraham WT, Adamson PB et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 2008; 51: 1073-9. doi: 10.1016/j.jacc.2007.10.061
92. Adamson PB, Smith AL, Abraham WT et al. Continuous autonomic assessment in patients with symptomatic heart failure. Circulation 2004; 110: 2389-94. doi: 10.1161/01.CIR.0000139841.42454.78
93. Clark RA, Inglis SC, McAlister FA et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ 2007; 334: 942. doi: 10.1136/bmj.39156.536968.55
94. Cleland JG, Lewinter C, Goode KM. Telemonitoring for heart failure: the only feasible option for good universal care? Eur J Heart Fail 2009; 11: 227-8. doi: 10.1093/eurjhf/hfp027